drugset / Trial / NCT01255046

Study of STA-1 as an Add-on Treatment to Donepezil

NCT01255046

Phase 2 Unknown 136 enrolled Sinphar Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of STA-1 vs placebo as an add-on treatment to donepezil in patients with mild to moderate Alzheimer's Disease (AD).

Timeline

Start
2015-12
Primary completion
2018-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator STA-1 Unknown 600 mg
Comparator Donepezil Small molecule 10 mg

Indications